
Endostatin in Renal and Cardiovascular Diseases
Author(s) -
Li Mei,
Popovic Zoran,
Chu Chang,
Krämer Bernhard K.,
Hocher Berthold
Publication year - 2021
Publication title -
kidney diseases
Language(s) - English
Resource type - Journals
eISSN - 2296-9357
pISSN - 2296-9381
DOI - 10.1159/000518221
Subject(s) - review article
Endostatin, a protein derived from the cleavage of collagen XVIII by the action of proteases, is an endogenous inhibitor known for its ability to inhibit proliferation and migration of endothelial cells, angiogenesis, and tumor growth. Angiogenesis is defined as the formation of new blood vessels from pre-existing vasculature, which is crucial in many physiological processes, such as embryogenesis, tissue regeneration, and neoplasia. Summary: Increasing evidence shows that dysregulation of angiogenesis is crucial for the pathogenesis of renal and cardiovascular diseases. Endostatin plays a pivotal role in the regulation of angiogenesis. Recent studies have provided evidence that circulating endostatin increases significantly in patients with kidney and heart failure and may also contribute to disease progression. Key Message: In the current review, we summarize the latest findings on preclinical and clinical studies analyzing the impact of endostatin on renal and cardiovascular diseases.